RT Journal Article
T1 Long-term safety of nine systemic medications for psoriasis: A cohort study using the Spanish Registry of Adverse Events for Biological Therapy in Dermatological Diseases (BIOBADADERM) Registry.
A1 Daudén, Esteban
A1 Carretero, Gregorio
A1 Rivera, Raquel
A1 Ferrándiz, Carlos
A1 Llamas-Velasco, Mar
A1 de la Cueva, Pablo
A1 Belinchón, Isabel
A1 Gómez-García, Francisco José
A1 Herrera-Acosta, Enrique
A1 Ruiz-Genao, Diana Patricia
A1 Ferrán-Farrés, Marta
A1 Alsina, Mercè
A1 Baniandrés-Rodríguez, Ofelia
A1 Sánchez-Carazo, José Luis
A1 Sahuquillo-Torralba, Antonio
A1 Fernández-Freire, Lourdes Rodriguez
A1 Vilar-Alejo, Jaime
A1 García-Donoso, Carmen
A1 Carrascosa, José Manuel
A1 Herrera-Ceballos, Enrique
A1 López-Estebaranz, José Luis
A1 Botella-Estrada, Rafael
A1 Segovia-Muñoz, Eva
A1 Descalzo, Miguel Angel
A1 García-Doval, Ignacio
A1 BIOBADADERM Study Group, 
K1 adverse effects
K1 anti-TNF
K1 anti-inflammatory agents
K1 biologic agents
K1 immunosuppressive agents
K1 long-term follow-up
K1 pharmacovigilance
K1 prospective cohort
K1 psoriasis/drug therapy
K1 registries
K1 safety
AB Registry studies broadly describing the safety of systemic drugs in psoriasis are needed. To describe the safety findings of the systemic drugs acitretin, adalimumab, apremilast, cyclosporine, etanercept, infliximab, methotrexate, secukinumab, and ustekinumab used for the treatment of moderate to severe psoriasis in patients included in the Spanish Registry of Adverse Events for Biological Therapy in Dermatological Diseases (BIOBADADERM) Registry. The incidence rate ratio (IRR) and adjusted IRR (including propensity scores) of identified adverse events for each drug, using methotrexate as reference, were determined by means of a prospective cohort. Our study included 2845 patients (8954 treatment cycles; 9642 patient-years). Ustekinumab and secukinumab had the lowest rate of adverse events for several of the system organ classes, with a statistically significant decreased rate ratio (IRR of  Observational study, drug allocation not randomized, depletion of susceptibles, and prescribed doses not registered. Our data provide comparative safety information in the real-life setting that could help clinicians selecting between available products.
YR 2020
FD 2020-03-22
LK http://hdl.handle.net/10668/15285
UL http://hdl.handle.net/10668/15285
LA en
DS RISalud
RD Apr 17, 2025